Base de dados : MEDLINE
Pesquisa : D03.383.742.698.253.488 [Categoria DeCS]
Referências encontradas : 1378 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 138 ir para página                         

  1 / 1378 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28330689
[Au] Autor:Jones NE; Kelleman MS; Simon HK; Stockwell JA; McCracken C; Mallory MD; Kamat PP
[Ad] Endereço:Division of Pediatric Emergency Medicine, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States. Electronic address: nicholas.e.jones@emory.edu.
[Ti] Título:Evaluation of methohexital as an alternative to propofol in a high volume outpatient pediatric sedation service.
[So] Source:Am J Emerg Med;35(8):1101-1105, 2017 Aug.
[Is] ISSN:1532-8171
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Propofol is a preferred agent for many pediatric sedation providers because of its rapid onset and short duration of action. It allows for quick turn around times and enhanced throughput. Occasionally, intravenous (IV) methohexital (MHX), an ultra-short acting barbiturate is utilized instead of propofol. OBJECTIVE: Describe the experience with MHX in a primarily propofol driven outpatient sedation program and to see if it serves as an acceptable alternative when propofol is not the preferred pharmacologic option. METHODS: Retrospective chart review from 2012 to 2015 of patients receiving IV MHX as their primary sedation agent. Data collected included demographics, reason for methohexital use, dosing, type of procedure, success rate, adverse events (AE), duration of the procedure, and time to discharge. RESULTS: Methohexital was used in 240 patient encounters. Median age was 4years (IQR 2-7), 71.8% were male, and 80.4% were ASA-PS I or II. Indications for MHX use: egg+soy/peanut allergy in 93 (38.8%) and mitochondrial disorder 9 (3.8%). Median induction bolus was 2.1mg/kg (IQR, 1.9-2.8), median maintenance infusion was 4.5mg/kg/h (IQR, 3.0-6.0). Hiccups 15 (6.3%), secretions requiring intervention 14 (5.8%), and cough 12 (5.0%) were the most commonly occurring minor AEs. Airway obstruction was seen in 28 (11.6%). Overall success rate was 94%. Median time to discharge after procedure completion was 40.5min (IQR 28-57). CONCLUSION: Methohexital can be used with a high success rate and AEs that are not inconsistent with propofol administration. Methohexital should be considered when propofol is not a preferred option.
[Mh] Termos MeSH primário: Assistência Ambulatorial
Anestésicos Intravenosos/administração & dosagem
Metoexital/administração & dosagem
Propofol/administração & dosagem
[Mh] Termos MeSH secundário: Assistência Ambulatorial/métodos
Criança
Pré-Escolar
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Masculino
Metoexital/farmacologia
Pacientes Ambulatoriais
Seleção de Pacientes
Guias de Prática Clínica como Assunto
Propofol/farmacologia
Estudos Retrospectivos
Estados Unidos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anesthetics, Intravenous); E5B8ND5IPE (Methohexital); YI7VU623SF (Propofol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170324
[St] Status:MEDLINE


  2 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27811495
[Au] Autor:Woodward EL; Xiong Z
[Ad] Endereço:From the *Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and †Harvard Medical School, Boston, Massachusetts.
[Ti] Título:Use of Methohexital and Dexmedetomidine for Maintenance of Anesthesia in a Patient With Mitochondrial Myopathy: A Case Report.
[So] Source:A A Case Rep;8(2):33-35, 2017 Jan 15.
[Is] ISSN:2325-7237
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Provision of anesthesia for patients with mitochondrial disorders is associated with a unique set of challenges. These disorders are rare, which complicates efforts to develop high quality, evidence-based guidelines to inform the perioperative management of those who suffer from them. Accordingly, case reports remain an important source of information regarding their care. Here we present the case of a 27-year-old female patient with mitochondrial myopathy and a history suggestive of malignant hyperthermia susceptibility who received general anesthesia for 2 consecutive surgeries. The induction agents included fentanyl, ketamine, and methohexital. The maintenance agents were methohexital, sufentanil, and dexmedetomidine.
[Mh] Termos MeSH primário: Anestesia Geral/métodos
Dexmedetomidina/administração & dosagem
Hipertermia Maligna/prevenção & controle
Metoexital/administração & dosagem
Miopatias Mitocondriais/cirurgia
[Mh] Termos MeSH secundário: Adulto
Feminino
Fentanila/administração & dosagem
Seres Humanos
Ketamina/administração & dosagem
Sufentanil/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
67VB76HONO (Dexmedetomidine); 690G0D6V8H (Ketamine); AFE2YW0IIZ (Sufentanil); E5B8ND5IPE (Methohexital); UF599785JZ (Fentanyl)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170119
[Lr] Data última revisão:
170119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161105
[St] Status:MEDLINE
[do] DOI:10.1213/XAA.0000000000000416


  3 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27687429
[Au] Autor:Johnson TJ; Porhomayon J; Nader ND; Eldesouki E; Smith K; Hobika GG
[Ad] Endereço:Department of Anesthesiology, University of Buffalo, Buffalo, New York, NY.
[Ti] Título:Hyperlipidemia sink for anesthetic agents.
[So] Source:J Clin Anesth;34:436-8, 2016 Nov.
[Is] ISSN:1873-4529
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We present a case that involves anesthetic resistance during anesthesia for electroconvulsive therapy. Despite adequate dosing of both intravenous and inhalation anesthetics, our patient was resistant to induction of the state of general anesthesia. Subsequently, we noticed extreme hyperlipidemia. We hypothesized that the patient's extreme hyperlipidemia served as an anesthetic "sink" and prevented the full dose of intravenous agents from quickly reaching their intended site of action.
[Mh] Termos MeSH primário: Anestésicos Inalatórios/administração & dosagem
Anestésicos Intravenosos/administração & dosagem
Hiperlipidemias/sangue
Lipoproteínas/metabolismo
Metoexital/farmacocinética
Propofol/farmacocinética
[Mh] Termos MeSH secundário: Adulto
Anestesia por Inalação
Anestesia Intravenosa
Anestésicos Inalatórios/farmacocinética
Anestésicos Intravenosos/farmacocinética
Transtorno Depressivo Resistente a Tratamento/terapia
Eletroconvulsoterapia
Seres Humanos
Masculino
Metoexital/administração & dosagem
Propofol/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anesthetics, Inhalation); 0 (Anesthetics, Intravenous); 0 (Lipoproteins); E5B8ND5IPE (Methohexital); YI7VU623SF (Propofol)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161001
[St] Status:MEDLINE


  4 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26806849
[Au] Autor:Fond G; Bennabi D; Haffen E; Brunel L; Micoulaud-Franchi JA; Loundou A; Lançon C; Llorca PM; Auquier P; Boyer L
[Ad] Endereço:Université Paris Est-Créteil, Pôle de psychiatrie des hôpitaux universitaires H Mondor DHU Pe-PSY, INSERM U955, Eq Psychiatrie translationelle, Fondation FondaMental Fondation de coopération scientifique en santé mentale, Créteil, France.
[Ti] Título:A Bayesian framework systematic review and meta-analysis of anesthetic agents effectiveness/tolerability profile in electroconvulsive therapy for major depression.
[So] Source:Sci Rep;6:19847, 2016 Jan 25.
[Is] ISSN:2045-2322
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to assess the efficacy and tolerability/acceptability of 6 anesthetic agents in ECT for depressive disorders. We systematically reviewed 14 double-blind randomized controlled trials (610 participants). Efficacy was measured by the mean scores on validated depression scales at 6 ECT (or the nearest score if not available), number of responders at the end of treatment and seizure duration. The acceptability was measured by the proportion of patients who dropped out of the allocated treatment, and the tolerability by the number of serious adverse events and post-treatment cognition assessment. After excluding the trials responsible for heterogeneity, depression scores of patients who were administered methohexital were found to be significantly more improved than those who received propofol (p = 0.001). On the contrary, those who were administered propofol had lower depression scores than those with thiopental at the end of treatment (p = 0.002). Compared to propofol, methohexital was found to be significantly associated with higher seizure duration (p = 0.018). No difference was found for the acceptability profile (all p > 0.05). In summary, ketamine and methohexital may be preferred to propofol or thiopental in regard of effectiveness in depression scores and increased seizure duration. Further studies are warranted to compare ketamine and methohexital.
[Mh] Termos MeSH primário: Anestésicos/uso terapêutico
Transtorno Depressivo Maior/tratamento farmacológico
Metoexital/uso terapêutico
Convulsões/tratamento farmacológico
[Mh] Termos MeSH secundário: Anestésicos/efeitos adversos
Teorema de Bayes
Transtorno Depressivo Maior/patologia
Eletroconvulsoterapia
Eletroencefalografia
Seres Humanos
Ketamina/efeitos adversos
Ketamina/uso terapêutico
Metoexital/efeitos adversos
Ensaios Clínicos Controlados Aleatórios como Assunto
Convulsões/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Anesthetics); 690G0D6V8H (Ketamine); E5B8ND5IPE (Methohexital)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160126
[St] Status:MEDLINE
[do] DOI:10.1038/srep19847


  5 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26669745
[Au] Autor:Li EH; Stork CE; Jim On SC; Bryson EO; Aloysi AS; Kellner CH
[Ad] Endereço:Icahn School of Medicine at Mount Sinai New York, NY Department of Psychiatry Icahn School of Medicine at Mount Sinai New York, NY charles.kellner@mssm.edu.
[Ti] Título:Additional Procedures Performed During Electroconvulsive Therapy Anesthesia.
[So] Source:J ECT;32(3):e7-8, 2016 Sep.
[Is] ISSN:1533-4112
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anestesia/métodos
Eletroconvulsoterapia/métodos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Anestésicos Intravenosos
Catatonia/psicologia
Catatonia/terapia
Feminino
Seres Humanos
Masculino
Metoexital
Conforto do Paciente
Propofol
Transtornos Psicóticos/psicologia
Transtornos Psicóticos/terapia
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Anesthetics, Intravenous); E5B8ND5IPE (Methohexital); YI7VU623SF (Propofol)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170302
[Lr] Data última revisão:
170302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151217
[St] Status:MEDLINE
[do] DOI:10.1097/YCT.0000000000000288


  6 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26548500
[Au] Autor:Bunney PE; Burroughs D; Hernandez C; LeSage MG
[Ad] Endereço:Department of Medicine, Minneapolis Medical Research Foundation, 701 Park Ave., Minneapolis, MN 55415, United States; Department of Medicine, University of Minnesota School of Medicine, 420 Delaware St. SE, Minneapolis, MN 55455, United States. Electronic address: pgrebenstein@mmrf.org.
[Ti] Título:The effects of nicotine self-administration and withdrawal on concurrently available chow and sucrose intake in adult male rats.
[So] Source:Physiol Behav;154:49-59, 2016 Feb 01.
[Is] ISSN:1873-507X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Carbohydrate intake, preference, and taste thresholds may be altered in current and former cigarette smokers, which may mediate weight gain and risk for obesity in individuals who quit smoking. Attempts to model these effects in rodents have primarily used noncontingent nicotine administration. The purpose of this research was to characterize changes in chow and sucrose intake in rats during a 23-h access model of i.v. nicotine self-administration (NSA), in which rats lever-pressed for chow, sucrose, and nicotine under concurrent fixed-ratio (FR) 1 schedules. Male rats were assigned to one of three groups that differed in food and drug availability. The Nicotine C+S group had concurrent access to nicotine, chow, and sucrose. The Saline C+S group had access to saline, chow, and sucrose. The Nicotine C-Only group had access to nicotine and chow, but not sucrose. Changes in food intake and weight gain were assessed during baseline, NSA, and nicotine withdrawal (i.e., saline extinction). Weight gain was significantly slowed during NSA and increased during withdrawal, but did not differ between the nicotine groups. NSA produced a significant decrease in both chow and sucrose intake. Gradual tolerance to nicotine's effects on sucrose, but not chow intake, occurred. During withdrawal, chow and sucrose intake increased, with a larger percent increase in sucrose intake compared to chow. The proportion of total food intake from sucrose was greater at the end of withdrawal compared to baseline, indicating a history of nicotine intake changed dietary preference. Combined, these results indicate that sucrose intake is more resistant to nicotine's appetite suppressant effects and withdrawal from nicotine produces a greater increase in sweet food intake alongside general increases in chow intake. Changes in overall food intake in current and ex-smokers may lead to increased risk for obesity and other health problems, potentially limiting the benefit of quitting smoking.
[Mh] Termos MeSH primário: Ingestão de Alimentos/efeitos dos fármacos
Comportamento Alimentar/efeitos dos fármacos
Preferências Alimentares/efeitos dos fármacos
Nicotina/administração & dosagem
Agonistas Nicotínicos/administração & dosagem
[Mh] Termos MeSH secundário: Análise de Variância
Anestésicos Intravenosos/farmacologia
Animais
Peso Corporal/efeitos dos fármacos
Condicionamento Operante/efeitos dos fármacos
Relação Dose-Resposta a Droga
Extinção Psicológica/efeitos dos fármacos
Masculino
Metoexital/farmacologia
Ratos
Esquema de Reforço
Autoadministração
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anesthetics, Intravenous); 0 (Nicotinic Agonists); 6M3C89ZY6R (Nicotine); E5B8ND5IPE (Methohexital)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151110
[St] Status:MEDLINE


  7 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26046456
[Au] Autor:Beimer NJ; Buchtel HA; Glynn SM
[Ad] Endereço:Department of Neurology, University of Michigan, Ann Arbor, Michigan, U.S.A.
[Ti] Título:One center's experience with complications during the Wada test.
[So] Source:Epilepsia;56(8):e110-3, 2015 Aug.
[Is] ISSN:1528-1167
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study aimed to define the number and type of complications associated with the Wada test at an academic medical center for comparison to previous reports. We performed a retrospective review of medical records for patients who underwent the Wada test at the University of Michigan between April 1991 and June 2013. Information was collected regarding the angiography procedure and the immediate postoperative period to assess for both clinical and angiographic complications. A total of 436 patients were identified who underwent the Wada procedure between April 1991 and June 2013, and 431 patients were included in the final analysis. Twenty-five patients (5.8%) had notable clinical events associated with the Wada test. Nine patients (2.1%) had clinical events meeting criteria for complication, which included seizures, status epilepticus, internal carotid artery vasospasm, inadvertent injection of anesthetic in the external carotid artery, and transient encephalopathy. No complications were associated with significant morbidity or mortality. This retrospective review of patients undergoing the Wada test found significantly fewer associated complications in comparison to previously published studies, with no patients experiencing long-term morbidity. The Wada test should be considered a safe diagnostic tool for lateralizing language and memory.
[Mh] Termos MeSH primário: Amobarbital
Anestésicos Intravenosos
Artéria Carótida Interna
Técnicas de Diagnóstico Neurológico/efeitos adversos
Epilepsia/diagnóstico
Lateralidade Funcional
Hipnóticos e Sedativos
Metoexital
Convulsões/etiologia
[Mh] Termos MeSH secundário: Estudos de Coortes
Epilepsia/cirurgia
Hematoma/etiologia
Seres Humanos
Injeções Intra-Arteriais
Cuidados Pré-Operatórios
Estudos Retrospectivos
Espasmo/etiologia
Estado Epiléptico/etiologia
Vasoconstrição
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anesthetics, Intravenous); 0 (Hypnotics and Sedatives); E5B8ND5IPE (Methohexital); GWH6IJ239E (Amobarbital)
[Em] Mês de entrada:1510
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150606
[St] Status:MEDLINE
[do] DOI:10.1111/epi.13046


  8 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:24755722
[Au] Autor:Yen T; Khafaja M; Lam N; Crumbacher J; Schrader R; Rask J; Billstrand M; Rothfork J; Abbott CC
[Ad] Endereço:From the *Departments of Anesthesiology and †Psychiatry, University of New Mexico School of Medicine, Albuquerque, NM; ‡University of New Mexico School of Medicine, Albuquerque, NM and §Clinical and Translational Science Center, University of New Mexico School of Medicine, Albuquerque, NM.
[Ti] Título:Post-electroconvulsive therapy recovery and reorientation time with methohexital and ketamine: a randomized, longitudinal, crossover design trial.
[So] Source:J ECT;31(1):20-5, 2015 Mar.
[Is] ISSN:1533-4112
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Methohexital, a barbiturate anesthetic commonly used for electroconvulsive therapy (ECT), possesses dose-dependent anticonvulsant properties, and its use can interfere with effective seizure therapy in patients with high seizure thresholds. Ketamine, an N-methyl-d-aspartate antagonist with epileptogenic properties not broadly used for ECT inductions, is a commonly used induction agent for general anesthesia. Recent studies suggest that the use of ketamine is effective in allowing successful ECT treatment in patients with high seizure thresholds without an increase in adverse effects. In this preliminary study, we directly compared the recovery and reorientation times of subjects receiving ketamine and methohexital for ECTs. METHODS: Twenty patients were randomized in a crossover design to receive methohexital and ketamine for ECT inductions in alternating fashion in 6 trials. Primary outcome measures were recovery time (voluntary movement, respiratory effort, blood pressure, consciousness, and O2 saturation) and reorientation time. Secondary outcome measures were individual recovery variables, adverse effect occurrence, and seizure duration. RESULTS: Overall recovery time was not significantly different between the 2 treatment arms (F(1, 17) = 0.72; P = 0.41). Reorientation time was faster in the methohexital arm (F(1, 17) = 9.23; P = 0.007). CONCLUSION: Ketamine inductions resulted in higher number of adverse effects, higher subject dropout rates, and a longer reorientation time with respect to methohexital inductions. No significant difference in postanesthesia recovery time was found between the ketamine and methohexital arms. Intolerability to ketamine affected a significant proportion of subjects and suggests that ketamine should remain as an alternative or adjunctive agent for patients with high seizure thresholds.
[Mh] Termos MeSH primário: Anestésicos Dissociativos/administração & dosagem
Anestésicos Intravenosos/administração & dosagem
Transtorno Depressivo Maior/terapia
Eletroconvulsoterapia/métodos
Ketamina/administração & dosagem
Metoexital/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Período de Recuperação da Anestesia
Anestésicos Dissociativos/efeitos adversos
Anestésicos Intravenosos/efeitos adversos
Estudos Cross-Over
Eletroencefalografia
Feminino
Seres Humanos
Ketamina/efeitos adversos
Masculino
Metoexital/efeitos adversos
Meia-Idade
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anesthetics, Dissociative); 0 (Anesthetics, Intravenous); 690G0D6V8H (Ketamine); E5B8ND5IPE (Methohexital)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:170123
[Lr] Data última revisão:
170123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140424
[St] Status:MEDLINE
[do] DOI:10.1097/YCT.0000000000000132


  9 / 1378 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24849145
[Au] Autor:Rajasekaran S; Hackbarth RM; Davis AT; Kopec JS; Cloney DL; Fitzgerald RK; Hassan NE; Ndika AN; Cornelius K; McCullough A; Sanfilippo D
[Ad] Endereço:1Pediatric Critical Care Medicine, Helen DeVos Children's Hospital, Grand Rapids, MI. 2Research Department, Grand Rapids Medical Education Partners, Grand Rapids, MI. 3Division of Pediatric Gastroenterology, Helen DeVos Children's Hospital, Grand Rapids, MI.
[Ti] Título:The safety of propofol sedation for elective nonintubated esophagogastroduodenoscopy in pediatric patients.
[So] Source:Pediatr Crit Care Med;15(6):e261-9, 2014 Jul.
[Is] ISSN:1529-7535
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To evaluate the safety of deep sedation provided by pediatric intensivists for elective nonintubated esophagogastroduodenoscopy. DESIGN: Retrospective observational study. SETTING: The sedation program at the Helen DeVos Children's Hospital. PATIENTS: A 4-year retrospective analysis was done on all outpatient elective pediatric esophagogastroduodenoscopy procedures performed in an intensivist run sedation program. Safety was examined by reviewing the occurrence of minor and major adverse effects during esophagogastroduodenoscopy sedation. Interventions were studied and reported. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: During the study period, 12,447 sedations were performed by the pediatric sedation program for various procedures. Two thousand one hundred forty-seven patients received 2,325 sedations (18.6%) for esophagogastroduodenoscopies performed for various indications. During the same time period, 53 (one for every 40 esophagogastroduodenoscopy sedations) were screened, found unsuitable for nonintubated sedation, and referred for general anesthesia. There were 2,254 sedations with propofol, 65 methohexital, five ketamine, and one fentanyl/midazolam sedation. Propofol sedation proved safe with a 2.1% prevalence of minor adverse events and no major events. Methohexital, on the other hand, had higher rate (p < 0.001) of minor events and one patient developed an anaphylactic reaction to its use. Regression analysis showed that other sedative agents were 8.6 times more likely to be associated with complications than propofol (odds ratio, 8.6; 95% CI, 4.1-18.2; p < 0.001). CONCLUSIONS: This study demonstrates that deep sedation for elective esophagogastroduodenoscopies can be provided safely in the appropriately screened patient by nonanesthesiologist physicians in a sedation program. These data suggest that propofol is a safe and effective agent for esophagogastroduodenoscopy sedation.
[Mh] Termos MeSH primário: Sedação Profunda/efeitos adversos
Endoscopia Gastrointestinal
Hipnóticos e Sedativos/efeitos adversos
Propofol/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Anestesiologia/economia
Anestésicos Intravenosos/efeitos adversos
Criança
Pré-Escolar
Cuidados Críticos/economia
Sedação Profunda/economia
Feminino
Seres Humanos
Masculino
Metoexital/efeitos adversos
Seleção de Pacientes
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anesthetics, Intravenous); 0 (Hypnotics and Sedatives); E5B8ND5IPE (Methohexital); YI7VU623SF (Propofol)
[Em] Mês de entrada:1504
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140523
[St] Status:MEDLINE
[do] DOI:10.1097/PCC.0000000000000147


  10 / 1378 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:24829975
[Au] Autor:Anderson TA; Kasser JR; Holzman RS
[Ti] Título:Anesthetic considerations in Sheldon-Hall syndrome.
[So] Source:Paediatr Anaesth;24(5):538-40, 2014 May.
[Is] ISSN:1460-9592
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Arthrogryposis is characterized by multiple, nonprogressive joint contractures which may be caused by maternal disorders such as oligohydramnios as well as fetal akinesia resulting from primary disorders of muscle, connective tissue, or neurologic tissue. Its prevalence is about 1 : 3000. Distal arthrogryposis (DA) is a heterogenous group of genetic disorders with a characteristic flexion of the joints of the hands and feet divided into different types with additional features. Sheldon-Hall Syndrome (SHS), also known as distal arthrogryposis type 2A (DA2A), has some nonorthopedic features of specific importance to anesthetic care.
[Mh] Termos MeSH primário: Androstanóis/uso terapêutico
Anestésicos Intravenosos
Intubação Intratraqueal/métodos
Fármacos Neuromusculares não Despolarizantes/uso terapêutico
[Mh] Termos MeSH secundário: Anormalidades Múltiplas
Artrogripose
Pré-Escolar
Pé Torto Equinovaro/cirurgia
Fentanila
Seres Humanos
Masculino
Metoexital
Anormalidades Dentárias/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androstanols); 0 (Anesthetics, Intravenous); 0 (Neuromuscular Nondepolarizing Agents); E5B8ND5IPE (Methohexital); UF599785JZ (Fentanyl); WRE554RFEZ (rocuronium)
[Em] Mês de entrada:1412
[Cu] Atualização por classe:140514
[Lr] Data última revisão:
140514
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140516
[St] Status:MEDLINE



página 1 de 138 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde